HEK293-GPRC5D Cells
2 622,00 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. HEK293-GPRC5D cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human G protein-coupled receptor family C group 5 member D (GPRC5D), an orphan receptor belonging to the class C G protein-coupled receptor family. GPRC5D exhibits highly restricted expression in normal tissues, with predominant expression reported in hair follicles, keratinized tissues, and plasma cells. Importantly, the receptor is highly expressed in multiple myeloma and certain other plasma cell malignancies, where its limited normal tissue distribution and robust tumor-associated expression have made it a prominent target for immunotherapeutic development, particularly in patients relapsing after BCMA-directed therapies. HEK293-GPRC5D cells are widely used in hematologic oncology research and therapeutic development for characterization of GPRC5D-targeted monoclonal antibodies, bispecific T-cell engagers, antibody-drug conjugates, and CAR-T or CAR-NK cell therapies. The stable recombinant expression system enables quantitative evaluation of antigen binding affinity, receptor occupancy, surface expression density, epitope specificity, and target-dependent cytotoxicity. These cells are particularly valuable for assessing the activity and selectivity of engineered immune cell therapies and T-cell redirecting biologics targeting GPRC5D-positive malignancies. Additional applications include flow cytometry assay development, reporter assays, high-throughput screening, and validation of receptor-specific imaging agents or diagnostic reagents. |
|---|---|
| Organisme | Human |
| Tissu | Fetal Kidney |
| Maladie | Transformed/immortalized; non-tumorigenic (HEK293 background) |
| Applications | GPRC5D-targeted antibody and bispecific antibody development; multiple myeloma therapeutics; CAR-T cell therapy; ADCC/CDC assays; flow cytometry; immuno-oncology screening |
Caractéristiques
| Âge | Fetus |
|---|---|
| Genre | Female |
| Morphologie | Epithelial-like |
| Type de cellule | Epithelial cells |
| Propriétés de croissance | Monolayer, adherent |
Données réglementaires
| Référence | HEK293-GPRC5D (Cytion catalog number 305989) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_6G25 |
| Statut OGM | GMO-S1: This HEK293 cell line contains a GPRC5D expression construct for multiple myeloma antigen studies and targeted therapy development. This classification applies only within Germany and may differ elsewhere. |
Données biomoléculaires
| Récepteurs exprimés | GPRC5D |
|---|
Manipulation
| Milieu de culture | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. |
| Réactif de dissociation | Trypsin-EDTA |
| Temps de doublement | approx. 24-36 hours |
| Repiquage | For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO2, and change the medium every 2-3 days. |
| Rapport de fractionnement | 1 to 5 |
| Densité de semis | 2 to 4 x 104 cells/cm2 |
| Renouvellement des fluides | 2 to 3 times per week |
| Rétablissement après le dégel | After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere (for adherent cultures) for at least 24 hours. |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|